Background: Individuals at ultra-high risk (UHR) for psychosis are understood to be the putative prodrome of overt psychosis, although there is still a possibility of false positives. The aim of the present study is to examine the potential links between multi-dimensional schizotypy, basic symptoms and emerging psychosis as defined by positive symptoms in individuals at ultra-high risk (UHR) for psychosis. Method: Sixty-one UHR individuals and 41 healthy controls were participated in baseline assessments. For multi-dimensional schizotypy assessments, Chapman's perceptual aberration scale, magical ideation scale, revised physical and social anhedonia scales, schizotypal ambivalence scales, and Eysenck's impulsiveness scale were used. Basic symptoms were assessed by using the schizophrenia-specific items of the Frankfurt complaints questionnaire (FCQ). 
(4) =14.242, p = 0.007].
Conclusion:
The addition of the self-reported basic symptoms and impulsiveness may be useful for a risk enhancement or stratification strategy in individuals at ultra-high risk for psychosis. Acknowledgement: This study was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI14C2242).
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Abstract
Cognitive control -a system that modulates the operation of other cognitive in the service of goal-directed behavior -is a core deficit in schizophrenia and its association with frontal cortical gamma oscillatory disturbances suggests a way to integrate molecular findings and models of cognition. Here we present data from first episode patients and address the role of concurrent cannabis usage in cognitive control impairments and its neurophysiological markers. 62 healthy controls were compared to 101 first episode patients performing the Preparing to Overcome Prepotency (POP) task, a cued stimulus-response reversal task, which in chronic schizophrenia patients, has been shown reduced engagement of prefrontal gamma activity. Psychosis subjects included patients with schizophrenia, schizoaffective disorder as well as other psychosis spectrum disorders, and had a variable history of cannabis usage. Patients showed impaired performance and complex spectral alterations of EEG activity. This included reduction of gamma activity in the frontal electrodes during high-control trials. However in the patient group, significant variability was explained by cannabis usage history. In particular a greater gamma power impairment was observed for subjects who had greater lifetime cannabis usage and heavy earlier cannabis use (<16 years old) appeared to exert a more deleterious effect than later use or more minimal use. The findings of this study suggest that the presence and time course of cannabis use history in first episode psychosis has a significant deleterious impact on frontal cortical gamma oscillations in the context of a cognitive control task. Cannabis effects during development are recognized as a critical area in psychosis research, possibly implicated in the genesis, presentation of the disorder and/or serving as an important confounding factor. The present data highlights how the development of specific and accurate models of cognitive impairment in psychosis
